产品说明书
Paclitaxel
 |
同义名 : | NSC 125973;NSC 125973，PTX |
| CAS号 : | 33069-62-4 | |
| 货号 : | A238238 | |
| 分子式 : | C47H51NO14 | |
| 纯度 : | 99% | |
| 分子量 : | 853.906 | |
| MDL号 : | MFCD00869953 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(122.96 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
IP 2% DMSO+2% Tween80+40% PEG300+water 6 mg/mL clear PO 0.5% CMC-Na 40 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Microtubules are the main constituent of mitotic apparatus in all eukaryotic cells, thus make it become an important pharmacological target for the treatment of tumor[1]. Paclitaxel can stabilize the microtubule formation through interacting with β-tubulin[2] and then promoting the polymerization and assembly of it[3]. Paclitaxel show the inhibitory effect on HMVEC proliferation with IC50 of 0.1 pM, much lower than the IC50 of 5-FU, camptothecin, cisplatin and doxorubicin[4]. Paclitaxel induces G2/M arrest of cell cycle, thus it also used in synchronization in cell cycle[5]. Paclitaxel was approved by FDA in treatment of ovarian cancer, breast cancer, non-small-cell lung cancer[6], etc.. | ||
| 作用机制 | Paclitaxel can stabilize the microtubule formation through interacting with β-tubulin[2] and then promoting the polymerization and assembly of it[3]. | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
| 697 | Growth Inhibition Assay | IC50=0.0015 μM | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | IC50=0.00796 μM | SANGER | ||
| A101D | Growth Inhibition Assay | IC50=0.0096 μM | SANGER | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.17mL 0.23mL 0.12mL |
5.86mL 1.17mL 0.59mL |
11.71mL 2.34mL 1.17mL |
| 参考文献 |
|---|